IDRA - Idera Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Idera Pharmaceuticals, Inc.

167 Sidney Street
Cambridge, MA 02139
United States
617-679-5500
http://www.iderapharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees62

Key Executives

NameTitlePayExercisedYear Born
Mr. Vincent J. MilanoPres, CEO & Director843.24kN/A1964
Mr. Louis J. Arcudi III, MBASr. VP of Operations, CFO, Treasurer & Assistant Sec.490.54kN/A1961
Dr. Jonathan YinglingSr. VP of Early Devel. & Chief Scientific OfficerN/AN/A1969
Mr. Robert Clayton FletcherSr. VP of Bus. Devel. & Strategic Planning513.24kN/A1963
Dr. Joanna C. HorobinSr. VP & Chief Medical OfficerN/AN/A1955
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Corporate Governance

Idera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.